Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
LGND stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.85B
- P/E (TTM)
- 30.90
- Forward P/E
- 24.54
- EPS (TTM)
- $9.49
- Dividend yield
- None
- Ex-dividend date
- Apr 3, 2007
- 52-week range
- 175.89 – 326.63
- Day range
- 292.47 – 301.27
- Volume / Avg
- 309.23K / 261.98K
- Beta
- —
- Shares outstanding
- 19.94M
- Next earnings
- Nov 5, 2026
52-week range
LGND stock today
On Oct 7, LGND ended the session at $293.26, shedding $3.68 (1.24%), versus the S&P 500's 0.22% decline. Shares are 10.2% below their 52-week high of $326.63, set on Jul 8, 2026 and 66.7% above the 52-week low of $175.89, in the middle of the past year's range. LGND is up 55.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 60.1%.
Ligand Pharmaceuticals trades at 30.9x its trailing twelve-month earnings per share of $9.49. Its forward P/E of 24.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Ligand Pharmaceuticals's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Ligand Pharmaceuticals
Company profileLigand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Todd C. Davis Ph.D.
- Headquarters
- Jupiter, FL
- Employees
- 47
- Website
- ligand.com
Financial highlights
Full financialsIn fiscal 2025, Ligand Pharmaceuticals generated $268.1 million in revenue, up 60.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $124.5 million, for a net margin of 46.4% versus a median of -1.8% in the prior 5 years. Operating margin was 15.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $268.09M | $167.13M | $131.31M | $196.25M | $241.54M |
| Growth | +60.40% | +27.28% | -33.09% | -18.75% | +47.68% |
| Net income | $124.45M | $-4.03M | $52.15M | $-33.36M | $57.14M |
| EPS (diluted) | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$344.25+17.39%
- Strong buy 3
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $1.42
- Last reported (Q2 2026)
- Aug 7, 2026
- EPS actual vs est.
- $2.22 vs —
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $9.36
- Ex-dividend date
- Apr 3, 2007
Ligand Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KNSAKiniksa Pharmaceuticals International plc Class A | 77.96 | +1.13% | $6.08B | vs LGND |
| RYTMRhythm Pharmaceuticals Inc. | 88.45 | -2.56% | $6.09B | vs LGND |
| BLTEBelite Bio Inc ADR | 156.08 | +0.30% | $6.29B | vs LGND |
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs LGND |
| MIRMMirum Pharmaceuticals Inc. | 80.64 | +1.75% | $5.24B | vs LGND |
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs LGND |
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs LGND |
| TVTXTravere Therapeutics Inc. | 53.44 | -4.54% | $5.04B | vs LGND |
Indexes, lists and sector
Appears in lists
Ligand Pharmaceuticals stock FAQ
What is Ligand Pharmaceuticals's stock price today?
LGND last traded at $293.26 as of Oct 7, 4:00 PM EDT, down 1.24% on the day. Prices are delayed at least 15 minutes.
Does Ligand Pharmaceuticals pay a dividend?
Yes. Ligand Pharmaceuticals pays $0.00 per share annually. The most recent dividend of $9.36 had an ex-dividend date of Apr 3, 2007.
When is Ligand Pharmaceuticals's next earnings date?
Ligand Pharmaceuticals is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $1.42.
What is LGND's P/E ratio?
LGND trades at a trailing P/E ratio of 30.90 and a forward P/E of 24.54.
Who is Ligand Pharmaceuticals's CEO?
Mr. Todd C. Davis Ph.D. is the chief executive officer of Ligand Pharmaceuticals Incorporated, which has about 47 employees.
Has LGND ever split its stock?
Yes. The most recent LGND stock split was a 1603-for-1000 split on Nov 2, 2022, one of 2 splits on record.
What is the LGND 52-week high?
The 52-week high for LGND is $326.63 and the 52-week low is $175.89. The stock is currently 10.2% below its high.